En vivo

PharmaVoiceAs M&A rebounds, here’s how pharmas can prepare to seal a deal FierceBiotechKardigan buttons up $400M upsized IPO to power heart drugs toward phase 3 FierceBiotechNovocure device fails to improve brain cancer patients’ survival in phase 3 test FierceBiotechNortiva purrs into action with long-acting Lynx platform salvaged from Langer startup Endpoints NewsInnoviva revives Lyndra's long-acting oral drug platform FierceBiotechBiogen inks $1B RayThera buyout to bag preclinical immunology assets Endpoints NewsModerna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departs Endpoints NewsEli Lilly's TuneLab hits 100 members, adding Chai's AI models CellChloroplast sunscreening by protein condensates confers high-light tolerance PharmaVoiceA new Westlake-backed biotech takes aim at migraines FierceBiotechF2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test Endpoints NewsAntifungal from F2G, Shionogi succeeds in Phase 3 study

Agilent 24 ene 2026

Will Agilent’s AI-Enabled Digital Pathology Push Reshape Agilent Technologies' (A) Diagnostics Narrative? - Yahoo Finance

Will Agilent’s AI-Enabled Digital Pathology Push Reshape Agilent Technologies' (A) Diagnostics Narrative? - Yahoo Finance

Contenido no disponible. Consulta la fuente original.